Clinical and Genetic Modifiers of Long-Term Survival in Heart Failure

Journal of the American College of Cardiology

Volumn 54, Issue 5, 2009, Pages 432-444

  Cresci, Sharon ^a   Kelly, Reagan J ^b   Cappola, Thomas P ^c   Diwan, Abhinav ^a   Dries, Daniel ^c   Kardia, Sharon L R ^b   Dorn II, Gerald W ^a  

^a WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF MICHIGAN SCHOOL OF PUBLIC HEALTH   (United States)

^c UNIVERSITY OF PENNSYLVANIA   (United States)

Author keywords

beta adrenergic receptor; beta blocker; G protein receptor kinase; gene polymorphism; heart failure

Indexed keywords

ALDOSTERONE ANTAGONIST; ANGIOTENSIN RECEPTOR ANTAGONIST; BETA 1 ADRENERGIC RECEPTOR; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CARVEDILOL; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; G PROTEIN COUPLED RECEPTOR KINASE 5; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; METOPROLOL;

ADULT; AFRICAN AMERICAN; AGED; ARTICLE; CAUCASIAN; DNA MODIFICATION; FEMALE; FOLLOW UP; GENETIC POLYMORPHISM; GENOTYPE; HEART FAILURE; HUMAN; MAJOR CLINICAL STUDY; MALE; MORTALITY; PRIORITY JOURNAL; RACE DIFFERENCE; SURVIVAL; TREATMENT RESPONSE;

ADRENERGIC BETA-ANTAGONISTS; AFRICAN AMERICANS; AGED; COHORT STUDIES; EUROPEAN CONTINENTAL ANCESTRY GROUP; FEMALE; G-PROTEIN-COUPLED RECEPTOR KINASE 5; GENOTYPE; HEART FAILURE; HUMANS; MALE; MIDDLE AGED; POLYMORPHISM, GENETIC; PROSPECTIVE STUDIES; RECEPTORS, ADRENERGIC, BETA; SIGNAL TRANSDUCTION; SURVIVAL RATE; TIME FACTORS; TREATMENT OUTCOME;

EID: 67650535224     PISSN: 07351097     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jacc.2009.05.009     Document Type: Article

References (60)

1. American Heart Association. 2002 Heart and Stroke Statistical Update. Dallas, Texas: American Heart Association, 2001. http://heartnet.bjmu.edu.cn/epi/usa/2002update.htm Accessed May 1, 2009
2. Kaye D.M., Smirk B., Finch S., Williams C., and Esler M.D. Interaction between cardiac sympathetic drive and heart rate in heart failure: modulation by adrenergic receptor genotype. J Am Coll Cardiol 44 (2004) 2008-2015
3. Lefkowitz R.J., Rockman H.A., and Koch W.J. Catecholamines, cardiac beta-adrenergic receptors, and heart failure. Circulation 101 (2000) 1634-1637
4. Bristow M.R. Beta-adrenergic receptor blockade in chronic heart failure. Circulation 101 (2000) 558-569
5. Domanski M.J., Krause-Steinrauf H., Massie B.M., et al. A comparative analysis of the results from 4 trials of beta-blocker therapy for heart failure: BEST, CIBIS-II, MERIT-HF, and COPERNICUS. J Card Fail 9 (2003) 354-363
6. Hunt S.A., Baker D.W., Chin M.H., et al. ACC/AHA guidelines for the evaluation and management of chronic heart failure in the adult: executive summary. A report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Committee to Revise the 1995 Guidelines for the Evaluation and Management of Heart Failure). J Am Coll Cardiol 38 (2001) 2101-2113
7. Gillum R.F. Heart failure in the United States 1970-1985. Am Heart J 113 (1987) 1043-1045
8. Gillum R.F. The epidemiology of cardiovascular disease in black Americans. N Engl J Med 335 (1996) 1597-1599
9. Dries D.L., Exner D.V., Gersh B.J., Cooper H.A., Carson P.E., and Domanski M.J. Racial differences in the outcome of left ventricular dysfunction. N Engl J Med 340 (1999) 609-616
10. Smedley B.D., Stith A.Y., and Nelson A.R. Unequal treatment: confronting racial and ethnic disparities in health care (IOM 2002 Report) (2003), National Academies Press, Washington, DC
11. Yancy C.W. Executive summary of the African-American Initiative. MedGenMed 9 (2007) 28
12. Young J.H., Chang Y.P., Kim J.D., et al. Differential susceptibility to hypertension is due to selection during the out-of-Africa expansion. PLoS Genet 1 (2005) e82
13. Deo R.C., Patterson N., Tandon A., et al. A high-density admixture scan in 1,670 African Americans with hypertension. PLoS Genet 3 (2007) e196
14. Zhu X., and Cooper R.S. Admixture mapping provides evidence of association of the VNN1 gene with hypertension. PLoS ONE 2 (2007) e1244
15. Helgason A., Páisson S., Thorleifsson G., et al. Refining the impact of TCF7L2 gene variants on type 2 diabetes and adaptive evolution. Nat Genet 39 (2007) 218-225
16. Leak T.S., Keene K.L., Langefeld C.D., et al. Association of the proprotein convertase subtilisin/kexin-type 2 (PCSK2) gene with type 2 diabetes in an African American population. Mol Genet Metab 92 (2007) 145-150
17. Campbell M., and Tishkoff S. African genetic diversity: implications for human demographic history, modern human origins, and complex disease mapping. Annu Rev Genomics Hum Genet 9 (2008) 403-433
18. Mehlotra R.K., Bockarie M.J., and Zimmerman P.A. CYP2B6 983T>C polymorphism is prevalent in West Africa but absent in Papua New Guinea: implications for HIV/AIDS treatment. Br J Clin Pharmacol 64 (2007) 391-395
19. Nyakutira C., Röshammar D., Chiqusta E., et al. High prevalence of the CYP2B6 516G-->T(*6) variant and effect on the population pharmacokinetics of efavirenz in HIV/AIDS outpatients in Zimbabwe. Eur J Clin Pharmacol 64 (2008) 357-365
20. Patin E., Barreiro L.B., Sabeti P.C., et al. Deciphering the ancient and complex evolutionary history of human arylamine N-acetyltransferase genes. Am J Hum Genet 78 (2006) 423-436
21. Brodde O.E. β-1 and β-2 adrenoceptor polymorphisms: functional importance, impact on cardiovascular diseases and drug responses. Pharmacol Ther 117 (2008) 1-29
22. Liggett S.B., Cresci S., Kelly R.J., et al. A GRK5 polymorphism that inhibits β-adrenergic receptor signaling is protective in heart failure. Nat Med 14 (2008) 510-517
23. Liggett S.B., Mialet-Perez J., Thaneemit-Chen S., et al. A polymorphism within a conserved beta(1)-adrenergic receptor motif alters cardiac function and beta-blocker response in human heart failure. Proc Natl Acad Sci U S A 103 (2006) 11288-11293
24. Mialet P.J., Rathz D.A., Petrashevskaya N.N., et al. Beta 1-adrenergic receptor polymorphisms confer differential function and predisposition to heart failure. Nat Med 9 (2003) 1300-1305
25. Rozen S., and Skaletsky H. Primer3 on the WWW for general users and for biologist programmers. Methods Mol Biol 132 (2000) 365-386
26. Marsh S., King C.R., Garsa A.A., and McLeod H.L. Pyrosequencing of clinically relevant polymorphisms. Methods Mol Biol 311 (2005) 97-114
27. Parmar M., and Machin D. Survival Analysis: A Practical Approach (1995), Wiley, New York, NY
28. R Development Core Team. A Language and Environment for Statistical Computing (2008), R Foundation for Statistical Computing, Vienna
29. Rathmore S.S., Foody J.M., Wang Y., et al. Race, quality of care, and outcomes of elderly patients hospitalized with heart failure. JAMA 289 (2003) 2517-2524
30. Yancy C.W., and Strong M. The natural history, epidemiology, and prognosis of heart failure in African Americans. Congest Heart Fail 10 (2004) 15-18
31. Yancy C.W., Fowler M.B., Colucci W.S., et al. Race and the response to adrenergic blockade with carvedilol in patients with chronic heart failure. N Engl J Med 344 (2001) 1358-1365
32. Eichhorn E.J., Domanski M.J., Krause-Steinrauf H., Bristow M.R., and Lavori P.W. A trial of the beta-blocker bucindolol in patients with advanced chronic heart failure. N Engl J Med 344 (2001) 1659-1667
33. The Merit HF Investigators. Effect of metoprolol CR/XL in chronic heart failure: Metoprolol CR/XL Randomised Intervention Trial in Congestive Heart Failure (MERIT-HF). Lancet 353 (1999) 2001-2007
34. Carson P., Ziesche S., Johnson G., Cohn J.N., and Vasodilator-Heart Failure Trial Study Group. Racial differences in response to therapy for heart failure: analysis of the vasodilator-heart failure trials. J Card Fail 5 (1999) 178-187
35. Exner D.V., Dries D.L., Domanski M.J., and Cohn J.N. Lesser response to angiotensin-converting enzyme inhibitor therapy in black as compared with white patients with left ventricular dysfunction. N Engl J Med 344 (2009) 1351-1357
36. Dorn II G.W., and Liggett S.B. Pharmacogenomics of beta-adrenergic receptors and their accessory signaling proteins in heart failure. Clinical Transl Med 1 (2008) 255-262
37. Podlowski S., Wenzel K., Luther H.P., et al. Beta1-adrenoceptor gene variations: a role in idiopathic dilated cardiomyopathy?. J Mol Med 78 (2000) 87-93
38. Liggett S.B., Mialet-Perez J., Thaneemit-Chen S., et al. A polymorphism within a conserved beta(1)-adrenergic receptor motif alters cardiac function and beta-blocker response in human heart failure. Proc Natl Acad Sci U S A 103 (2006) 11288-11293
39. Pacanowski M.A., Zineh I., Li H., et al. Adrenergic gene polymorphisms and cardiovascular risk in the NHLBI-sponsored Women's Ischemia Syndrome Evaluation. J Transl Med 6 (2008) 11
40. Kohout T.A., and Lefkowitz R.J. Regulation of G protein-coupled receptor kinases and arrestins during receptor desensitization. Mol Pharmacol 63 (2003) 9-18
41. Wang W.C., Mihlbachler K.A., Bleecker E.R., Weiss S.T., and Liggett S.B. A polymorphism of G-protein coupled receptor kinase5 alters agonist-promoted desensitization of beta2-adrenergic receptors. Pharmacogenet Genomics 18 (2008) 729-732
42. Diaz R.A., Obasohan A., and Oakley C.M. Prediction of outcome in dilated cardiomyopathy. Br Heart J 58 (1987) 393-399
43. Felker G.M., Thompson R.E., Hare J.M., et al. Underlying causes and long-term survival in patients with initially unexplained cardiomyopathy. N Engl J Med 342 (2000) 1077-1084
44. Yancy C.W. Heart failure in African Americans: a cardiovascular enigma. J Card Fail 6 (2000) 183-186
45. Hall W.D. Representation of blacks, women, and the very elderly (aged > or = 80) in 28 major randomized clinical trials. Ethn Dis 9 (1999) 333-340
46. Pamboukian S.V., Costanzo M.R., Meyer P., Bartlett L., Mcleod M., and Heroux A. Influence of race in heart failure and cardiac transplantation: mortality differences are eliminated by specialized, comprehensive care. J Card Fail 9 (2003) 80-86
47. Rosamond W., Flegal K., Furie K., et al. Heart disease and stroke statistics-2008 update: a report from the American Heart Association Statistics Committee and Stroke Statistics Subcommittee. Circulation 117 (2008) e25-e146
48. Bristow M.R. Changes in myocardial and vascular receptors in heart failure. J Am Coll Cardiol 22 (1993) 61A-71A
49. Premont R.T., Koch W.J., Inglese J., and Lefkowitz R.J. Identification, purification, and characterization of GRK5, a member of the family of G protein-coupled receptor kinases. J Biol Chem 269 (1994) 6832-6841
50. Mason D.A., Moore J.D., Green S.A., and Liggett S.B. A gain-of-function polymorphism in a G-protein coupling domain of the human beta1-adrenergic receptor. J Biol Chem 274 (1999) 12670-12674
51. Mialet P.J., Rathz D.A., Petrashevskaya N.N., et al. Beta 1-adrenergic receptor polymorphisms confer differential function and predisposition to heart failure. Nat Med 9 (2003) 1300-1305
52. White H.L., de Boer R.A., Magbool A., et al. An evaluation of the beta-1 adrenergic receptor Arg389Gly polymorphism in individuals with heart failure: a MERIT-HF sub-study. Eur J Heart Fail 5 (2003) 463-468
53. De Groote P., Helbecque N., Lamblin N., et al. Association between beta-1 and beta-2 adrenergic receptor gene polymorphisms and the response to beta-blockade in patients with stable congestive heart failure. Pharmacogenet Genomics 15 (2005) 137-142
54. Terra S.G., Hamilton K.K., Pauly D.F., et al. Beta1-adrenergic receptor polymorphisms and left ventricular remodeling changes in response to beta-blocker therapy. Pharamcogenet Geonomics 15 (2005) 227-234
55. Chen L., Meyers D., Javorsky G., et al. Arg389Gly-beta1-adrenergic receptors determine improvement in left ventricular systolic function in nonischemic cardiomyopathy patients with heart failure after chronic treatment with carvedilol. Pharmacogenet Genomics 17 (2007) 941-949
56. Biolo A., Clausell N., Santos K.G., et al. Impact of beta1-adrenergic receptor polymorphisms on susceptibility to heart failure, arrhythmogenesis, prognosis, and response to beta-blocker therapy. Am J Cardiol 102 (2008) 726-732
57. Sehnert A.J., Daniels S.E., Elashoff M., et al. Lack of association between adrenergic receptor genotypes and survival in heart failure patients treated with carvedilol or metoprolol. J Am Coll Cardiol 52 (2008) 644-651
58. Kurnik P.B., Li C., Sofowora G.G., et al. Beta-1-adrenoceptor genetic variants and ethnicity independently affect response to beta-blockade. Pharmacogenet Genoomics 18 (2008) 895-902
59. Akhter S.A., D'Souza K.M., Petrashevskaya N.N., Mialet-Perez J., and Liggett S.B. Myocardial beta1-adrenergic receptor polymorphisms affect functional recovery after ischemic injury. A J Physiol Heart Circ Physiol 290 (2006) H1427-H1432
60. Haiman C.A., Patterson N., Freedman M.L., et al. Multiple regions within 8q24 independently affect risk for prostate cancer. Nat Genet 39 (2007) 638-644